0Shares0000Chelsea forward Eden Hazard has been tipped to win the Premier League Golden Boot by his manager Maurizio Sarri © AFP / Glyn KIRKLONDON, United Kingdom, Sep 17 – Eden Hazard can score 40 goals this season and win the Premier League Golden Boot, according to Chelsea boss Maurizio Sarri after the Belgium forward scored a hat-trick to maintain the club’s perfect start to the season.Sarri believes Hazard can become the best player in Europe and outstrip even arch poachers Harry Kane and Mohamed Salah following his three goals in a 4-1 victory against Cardiff on Saturday. “We have spoken and I told him he can score 40 goals,” said the former Napoli manager. “He has to improve some things, but he can do it.”Hazard himself has hailed Olivier Giroud as the world’s best target man after the World Cup-winning striker laid on two goals for him.Giroud is yet to find the net for Chelsea this season but already has three assists in five Premier League games while Hazard has found the net five times.And the 27-year-old paid tribute to the Frenchman for creating his first two goals at Stamford Bridge on Saturday.“Olivier’s a target man, maybe the best in the world, I think so,” said Hazard.“When he gets the ball he can hold the ball and we can go in deep with him, so for us it’s a pleasure to play with him.”Despite Chelsea’s fluency in attack, Sarri is aware the Stamford Bridge team must improve their defending.The Italian boss wants to turn Chelsea into the best team in England but says Liverpool and defending champions Manchester City will be the league’s pacesetters.“Eight players joined us this summer,” he said. “So I think it’s normal that in this period we have some defensive problems. We can cope with the problems with the quality in the offensive phase, but not in the defensive phase.“So I have to organise better the defensive phase and the players have to understand that. I think my opinion in this moment, two teams, Liverpool and Manchester City, are better than us.“We have to improve step by step. My target is to become the best team in England in one year, 18 months. That’s the target.”0Shares0000(Visited 1 times, 1 visits today)
“These are fairly unusual events,” said Shames. He noted that in preapproval testing of the patch on about 3,000 women there were two reports of blood clots, but one involved a woman who had had surgery. The ongoing studies also are looking at the risk of heart attacks and strokes among users of the two types of contraception. Currently there is no difference but the numbers are small and it will take another 18 months to see if a difference occurs, Shames said. The company said that the risk of clots remains rare and that they have been reported as a potential risk of all hormonal contraceptives. Release of the interim results comes four months after the Food and Drug Administration warned women that the increased levels of hormones released by the patch put them at higher risk of blood clots and other serious side effects. Ortho said it shared the results of the latest studies with the FDA. Additions to the patch label made in November warned women that they would be exposed to about 60 percent more estrogen than those who use birth-control pills. Since the patch went on sale in 2002, more than 4 million women have used it. The investigation by The Associated Press found that patch users die and suffer blood clots at a rate three times higher than women taking the pill. About a dozen women died in 2004 from blood clots believed linked to use of the patch, the AP reported. Dozens more suffered strokes and other clot-linked problems. Health officials warn that women who smoke should not use the patch, since smoking increases the risk of stroke and heart attack. 160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set! WASHINGTON – A new study shows that women using the Ortho Evra birth-control patch have double the risk of developing blood clots than those who take the pill, the Food and Drug Administration said Friday. But the agency said the results are preliminary and do not require immediate action other than advising women to discuss the risk with their doctor. The results of the study, and another that found no increased risk, were made public Thursday by the patch’s manufacturer. “The results are preliminary and further evaluation is necessary to understand what these results mean,” Dr. Daniel Shames, director of the division of reproductive and urological drug products at FDA, said at a briefing. AD Quality Auto 360p 720p 1080p Top articles1/5READ MORECasino Insider: Here’s a look at San Manuel’s new high limit rooms, Asian restaurant The finding comes from one of two studies comparing the patch and pill, said Ortho Women’s Health & Urology, maker of the once-a-week patch. The Raritan, N.J.-based company is owned by Johnson & Johnson. Last year an investigation by The Associated Press, citing federal death and injury reports, found higher rates of blood clots in women using the patch. The first study found no increased risk of clots but the interim results from the second study suggested a twofold increase in the risk of venous thromboembolic events, or clots in the legs and lungs, in women using the patch, Ortho said. However, because the confidence intervals of the results for the two forms of contraceptive overlap, there actually may be no increased risk from the patch or it may be more than twice, Shames said at a briefing. He said the risk of a nonfatal blood clot is about one per year in 10,000 women not using a contraceptive. For those using a hormonal contraceptive such as the patch or pill the risk rises to between three and five, he said.